Complementary and alternative medical therapies in multiple sclerosis - The American Academy of Neurology Guidelines: A commentary

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 1972-1978

  Yadav, Vijayshree ^a,b   Narayanaswami, Pushpa ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CANNABIS; CREATINE; CYANOCOBALAMIN; FISH OIL; GINKGO BILOBA EXTRACT; GLUCOSAMINE SULFATE; HISTAMINE; INOSINE; LEVACECARNINE; LINOLEIC ACID; LOFEPRAMINE; NABIXIMOLS; NALTREXONE; PHENYLALANINE; TETRAHYDROCANNABINOL; THREONINE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; APITHERAPY; ARTICLE; COGNITION; DEPRESSION; DIET SUPPLEMENTATION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FATIGUE; FEEDBACK SYSTEM; GINKGO BILOBA; HIPPOTHERAPY; HUMAN; HYPERBARIC OXYGEN; HYPNOSIS; LOW FAT DIET; MAGNETOTHERAPY; MASSAGE; MINDFULNESS; MULTIPLE SCLEROSIS; MUSCLE RELAXATION; MUSIC THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLEXOLOGY; SHORT COURSE THERAPY; SPASTICITY; YOGA; UNITED STATES;

COMPLEMENTARY THERAPIES; HUMANS; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; UNITED STATES;

EID: 84916878623     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.10.011     Document Type: Article

References (53)

1. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19(Suppl 2):S15-S20.
2. Evans C, Beland SG, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the americas: A systematic review. Neuroepidemiology. 2013;40:195-210.
3. Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Mult Scler. 2008;14:1113-1119.
4. Apel A, Greim B, Konig N, Zettl UK. Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. J Neurol. 2006;253:1331-1336.
5. National Center for Complementary and Alternative Medicine. http://nccam.nih.gov/health/whatiscam. Accessed March 27, 2013.
6. Yadav V, Bever C Jr, Bowen J, et al. Summary of evidencebased guideline: Complementary and alternative medicine in multiple sclerosis: Report of the guideline development subcommittee of the American Academy of N\neurology. Neurology. 2014;82:1083-1092.
7. Clinical practice guideline process manual: 2004 Edition. St. Paul, MN: American Academy of Neurology; 2005.
8. Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in alzheimer disease. Arch Neurol. 1998;55:1409-1415.
9. Diamond B, Johnson S, Torsney K, et al. Complementary and alternative medicines in the treatment of dementia: An evidence-based review. Drugs Aging. 2003;20:981-998.
10. Vorberg G. Ginkgo biloba extract (GBE): A long-term study of chronical cerebral insufficiency in geriatric patients. Clin Trials J. 1985;22:149-157.
11. Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial. Mult Scler. 2007;13:376-385.
12. Lovera JF, Kim E, Heriza E, et al. Ginkgo biloba does not improve cognitive function in MS: A randomized placebocontrolled trial. Neurology. 2012;79:1278-1284.
13. Johnson SK, Diamond BJ, Rausch S, et al. The effect of ginkgo biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial. Explore (NY). 2006;2:19-24.
14. Diamond BJ, Johnson SK, Kaufman M, et al. A randomized controlled pilot trial: The effects of EGb 761 on information processing and executive function in multiple sclerosis. Explore (NY). 2013;9:106-107.
15. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517-1526.
16. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10:417-424.
17. Zajicek JP, Hobart JC, Slade A, et al, MUSEC Research Group. Multiple sclerosis and extract of cannabis: Results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-1132.
18. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-1669.
19. Freeman RM, Adekanmi O, Waterfield MR, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: A multicentre, randomised placebocontrolled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:636-641.
20. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.
21. Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 1987;7:39-50.
22. Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62:1105-1109.
23. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58:1404-1407.
24. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441.
25. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812-819.
26. Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16:1349-1359.
27. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebocontrolled, parallel-group study of sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451-459.
28. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebo-controlled trial. CMAJ. 2012; 184:1143-1150.
29. Greenberg HS, Werness SA, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994; 55:324-328.
30. SWANK RL. Treatment of multiple sclerosis with low-fat diet. AMA Arch Neurol Psychiatry. 1953;69:91-103.
31. Swank RL. Multiple sclerosis: Twenty years on low fat diet. Arch Neurol. 1970;23:460-474.
32. Torkildsen O, Wergeland S, Bakke S, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS study): A randomized, double-blind, placebocontrolled trial. Arch Neurol. 2012;69:1044-1051.
33. Weinstock-Guttman B, Baier M, Park Y, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 2005;73:397-404.
34. Bates D, Cartlidge NE, French JM, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52:18-22.
35. Berne-Fromell K, Fromell H, Lundkvist S, Lundkvist P. Is multiple sclerosis the equivalent of Parkinson's disease for noradrenaline? Med Hypotheses. 1987;23:409-415.
36. Loder C. Standing in the sunshine: the story of the multiple sclerosis breakthrough. London: Century; 1996.
37. Wade DT, Young CA, Chaudhuri KR, Davidson DL. A randomised placebo controlled exploratory study L-phenylalanine (the "cari loder regime") in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:246-249.
38. Somerfield SD, Stach JL, Mraz C, et al. Bee venom melittin blocks neutrophil O2- production. Inflammation. 1986;10:175-182.
39. Banks BE, Dempsey CE, Vernon CA, et al. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990;99:350-354.
40. Wesselius T, Heersema DJ, Mostert JP, et al. A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology. 2005;65:1764-1768.
41. Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand, and foot reflexology. Obstet Gynecol. 1993;82:906-911.
42. Hughes CM, Smyth S, Lowe-Strong AS. Reflexology for the treatment of pain in people with multiple sclerosis: A double-blind randomised sham-controlled clinical trial. Mult Scler. 2009;15:1329-1338.
43. Siev-Ner I, Gamus D, Lerner-Geva L, Achiron A. Reflexology treatment relieves symptoms of multiple sclerosis: A randomized controlled study. Mult Scler. 2003;9:356-361.
44. Miller L, McIntee E, Mattison P. Evaluation of the effects of reflexology on quality of life and symptomatic relief in multiple sclerosis patients with moderate to severe disability; a pilot study. Clin Rehabil. 2013;27:591-598.
45. Mackereth PA, Booth K, Hillier VF, Caress AL. Reflexology and progressive muscle relaxation training for people with multiple sclerosis: A crossover trial. Complement Ther Clin Pract. 2009;15:14-21.
46. Sandyk R. Rapid normalization of visual evoked potentials by picoTesla range magnetic fields in chronic progressive multiple sclerosis. Int J Neurosci. 1994;77:243-259.
47. Guseo A. Pulsing electromagnetic field therapy of multiple sclerosis by the gyuling-bordacs device: Double-blind, cross-over and open studies. J Bioelect. 1987;6:23-35.
48. Piatkowski J, Kern S, Ziemssen T. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: A randomized, double-blind controlled trial. J Altern Complement Med. 2009;15:507-511.
49. Richards TL, Lappin MS, Acosta-Urquidi J, et al. Double-blind study of pulsing magnetic field effects on multiple sclerosis. J Altern Complement Med. 1997;3:21-29.
50. de Carvalho ML, Motta R, Konrad G, et al. A randomized placebocontrolled cross-over study using a low frequency magnetic field in the treatment of fatigue in multiple sclerosis. Mult Scler. 2012;18:82-89.
51. Mostert S, Kesselring J. Effect of pulsed magnetic field therapy on the level of fatigue in patients with multiple sclerosis-a randomized controlled trial. Mult Scler. 2005;11:302-305.
52. Lappin MS, Lawrie FW, Richards TL, Kramer ED. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: A double-blind, placebo controlled trial. Altern Ther Health Med. 2003;9:38-48.
53. Nielsen JF, Klemar B, Hansen HJ, Sinkjaer T. A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995;58:254-255.